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Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to mutations in the α-galacto-
sidase A gene (GLA) that result in absent ormarkedly reduceα-galactosidase A (α-GalA) enzymatic activity. As a
result, the major glycosphingolipid substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine
(LysoGb3) accumulate in plasma, urine and tissue lysosomes. In females, the diagnosis can be complicated by
the fact that 40–50% of GLA-mutation conﬁrmed heterozygotes have normal or only slightly decreased leukocyte
α-GalA activities. Recently, LysoGb3 has been appreciated as a novel FD biomarker, especially for therapeutic
monitoring.
Methods: Among our GLA-mutation proven FD patients, we screened 18 heterozygotes whose leukocyte α-GalA
activity was determined at initial diagnosis. For these females, we measured their serum LysoGb3 levels using
highly-sensitive electrospray ionization liquid chromatography tandem mass spectrometry.
Results:We identiﬁed three unrelated females in whom the accumulating LysoGb3 was increased, whereas their
leukocyte α-GalA activities were in the normal range.
Conclusion: LysoGb3 serves as an useful biomarker to improve the diagnosis of FD heterozygotes and for thera-
peutic evaluation and monitoring.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage disorder
caused by mutations in the α-galactosidase A (GLA) gene leading to
markedly decreased or absent α-GalA enzyme activity [1,2]. The enzy-
matic defect leads to glycosphingolipid accumulation in plasma, urine
and tissue lysosomes. The resulting clinical manifestations include kid-
ney and heart failure, cerebrovascular disease and premature demise.
Males are more severely affected than female heterozygotes, whose
manifestations can range from asymptomatic to rarely as severely
affected as males [1,2].
Currently, the diagnosis of affected males involves the demonstra-
tion of markedly decreased α-GalA activity in plasma, leucocytes or
dried blood spots (DBS), which can be conﬁrmed by GLAmutation anal-
ysis [1]. However, due to random X-chromosomal inactivation, at least
40% of GLA-mutation conﬁrmed heterozygotes have normal or slightly
decreased α-GalA activity requiring GLA sequencing to conﬁrm hetero-
zygosity [2–4].
The phenotypic heterogeneity also complicates the clinical diagnosis
of FD in females. There are twomajor subtypes, the Type 1 “Classic” and
the Type 2 “Later-Onset” phenotypes [4]. Affectedmaleswith the Type 2
phenotype have residual α-GalA activity, Later-Onset cardiac and/or
renal disease, and lack the major early-onset classical manifestations,
including angiokeratoma, acroparesthesias, hypohidrosis, and the ocu-
lar abnormalities [5–7]. Even genetic testing of patients at-risk or suspi-
cious for FD has been compromised by the recently recognized
occurrence of various benign missense mutations [8–10].
Previously, increased plasma or urine levels of globotriaosylceramide
(Gb3) were used to help identify heterozygosity, but its analysis is labo-
rious andmulti-procedural [11]. More recently, the easier measurement
of its deacylated form, globotriaosylsphingosine (LysoGb3) has become
appreciated as a novel diagnostic tool that can classify Classic and
Later-Onset males [12,13].
Here, we report three unrelated heterozygotes among the FD
patients treated or followed at the University Hospital Zurich with
increased LysoGb3, whereas their leukocyte α-GalA activities were in
the normal range. In thesewomen, the serum LysoGb3 levelswere useful
diagnostic markers to identify heterozygotes who should be evaluated
for treatment.
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2. Methods
2.1. Patients and clinical work-up
This study was conducted in accordance with the principles of the
Helsinki Declaration. All patients signed a written informed consent.
All authors have read and approved the manuscript.
Between January 2014 and December 2016, blood for biobanking
was drawn from 61 consecutive FD patients (36 females, 59%) at the
University Hospital Zurich, Zurich, Switzerland, all with a GLA-mutation
conﬁrmed diagnosis, who presented for routine annual examinations at
our FD center. In 11 of these patients (5 females), kidney biopsies had
been performed, all of which had the typical FD pathology including
the prominent Gb3 accumulation in vascular endothelial, interstitial
and mesangial cells, and in particular, in podocytes (Fig. 1) [14]. For
serum LysoGb3 levels, blood samples were centrifuged and serum was
immediately frozen at −80 °C. All patients had a comprehensive
work-up, including medical history, cardiac, renal, and neurological
evaluations. In this retrospective cohort study, all clinical and routine
laboratory results including α-GalA activities were obtained from the
patients` medical records. α-GalA activities were originally determined
at the time of diagnosis in the males and mutation analyses were per-
formed in all females. For this study, we screened the 18 heterozygotes
who previously had a documented α-GalA activity assay at the original
diagnosis. For these heterozygotes, we determined the serum LysoGb3
levels.
2.2. Phenotyping
Phenotyping was based on GLA mutation type: frame-shift, non-
sense, consensus splice-site mutations, large insertions and deletions,
and some missense mutations, which result in no or b2% of mean nor-
mal enzymatic activity were classiﬁed as having the Type 1 Classic phe-
notype. In contrast, some missense and some alternative splicing
mutations result in enzymes with residual enzymatic activity and the
Type 2 Later-Onset phenotype. To determine if the missense mutations
caused the Classic or Later-Onset phenotype, clinical data, substrate
levels, and in vitro expression assays were evaluated to determine the
mutation's phenotype [7,8].
2.3. LysoGb3 measurement
Serum LysoGb3 levels were measured by highly-sensitive
electrospray ionization liquid chromatography tandemmass spectrom-
etry (ESI LC-MS/MS) on a Shimadzu 8050 class Imedical device using an
adaptedmethod fromGold et al. [15]. A 7-point serum calibrator and an
internal standard for LysoGb3 quantiﬁcation (covering the analytic
range from 0 to 120 ng/mL; lower limit of quantiﬁcation: 0.3 ng/mL),
and three calibrator levels (3, 30 and 100 ng/mL) for quality control
were used (ARCHIMED Life Science GmbH, Vienna, Austria; www.
archimedlife.com). Further experimental details on mass spectrometric
conditions and sample work-up are available on request.
The reference range was deﬁned as the prediction interval that in-
cluded 95% of values of a reference group: cut-off ≤ 1.1 ng/mL.
3. Results
3.1. Fabry disease diagnosis in three female patients with normal α-GalA
activity
In our study cohort of 61 patients, there were 36 GLA-mutation con-
ﬁrmed heterozygotes. Of these, 18 previously had α-GalA activity
Fig. 1.Histologicalﬁndings of FabryDisease in a kidney biopsy. A: Lysosomal inclusionswith lamellated structures–myeloid bodies in podocytes (TEM,×2800). B:Highermagniﬁcation of
the podocyte shows lysosomes packed with storage material. Courtesy Dr. Ariana Gaspert, Pathology Department, University Hospital Zurich, Switzerland.
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determinations, and of these, three had normalα-GalA activities and in-
creased serum LysoGb3 levels, as described in detail below:
Female 1 was 55 years old when she was admitted to the hospital
with her third cryptogenic stroke, the ﬁrst having occurred when she
was 50 years old. At initial examination, the patient also described burn-
ing sensations in her hands and feet and an inability to sweat. Her son
died at 28 years old from recurrent epileptic seizures. He also
complained of burning paresthesias in his hands and feet. Her mother
died at 78 years; her father died of a myocardial infarction at the age
of 65 years.
Her clinical examination revealed a few angiokeratomas on her
trunk, and a slit-lamp examination revealed the characteristic cornea
verticillata. Laboratory studies demonstrated normal kidney function
and microalbuminuria (urinary albumin/creatinine 4.2 mg/mmol).
GLA mutation analysis identiﬁed GLA pathologic missense mutation
c.796G N T (p.Asp266Tyr) which made her heterozygote diagnosis.
This previously reported mutation causes the Classic phenotype [16].
Female 2was diagnosed with FD at 39 years of age by family mu-
tation screening. Her asymptomatic daughter was incidentally found
to have proteinuria at 11 years. The daughter's kidney biopsy re-
vealed myelin-ﬁgures in podocyte lysosomes by electron microsco-
py. Female 2's father died of kidney failure at 43 years of age. Her
paternal aunt had left ventricular hypertrophy and a pacemaker.
She died at 67 years of kidney failure following a hip fracture
operation. The clinical examination of Female 2 revealed no
angiokeratoma, but the slit-lamp examination showed cornea
verticillata. Laboratory studies demonstrated normal kidney
function and microalbuminuria (urinary albumin/creatinine 3.6
mg/mmol). Genetic testing conﬁrmed the pathogenic family mis-
sense mutation c.1033 T N C (p.Ser345Pro). This previously reported
missense mutation causes the Classic phenotype [16].
Female 3 suffered from chronic acroparesthesias and was diag-
nosed with FD at 12 years old by family screening. Her 41 year old
maternal uncle had acroparesthesias, myalgias, anhidrosis, protein-
uria and renal insufﬁciency, which led to a kidney biopsy. Electron
microscopy revealed numerous lamellar inclusions in the lysosomes
of podocytes, mesangial, vascular endothelial and tubular cells
and genetic testing was undertaken. Another maternal uncle com-
mitted suicide at 28 years of age due to recurrent excruciating
acroparesthesias shortly before the family was diagnosed as having
FD. The 31 year old mother of Female 3, a 38 year old maternal
uncle, and a 36 year old maternal aunt also had the family mutation.
Female 3 did not have angiokeratomas, however, the slit-lamp ex-
amination showed cornea verticillata. Laboratory studies demon-
strated normal kidney function and proteinuria of b0.5 g per 24 h.
However, the electron microscopy of her kidney biopsy revealed nu-
merous lamellar inclusions in podocyte lysosomes, typical of the
Fabry nephropathy. Genetic testing conﬁrmed the presence of the
pathogenic family mutation c.744_745delTA (p.Phe248LeufsX7).
This previously reported frameshift mutation causes the Classic
phenotype [16].
All three heterozygotes had Classic mutations with normal
leukocyte α-GalA activities and markedly elevated serum LysoGb3.
Their clinical and biochemical characteristics are summarized in the
Table 1. All symptoms described in the text and Tables were diagnosed
prior to enzyme replacement therapy (ERT).
3.2. Clinical and biochemical parameters of two female patients with nor-
mal α-galactosidase activity and normal LysoGb3 levels
Two of the 18 females who had α-GalA activity determinations,
had normal α-GalA activities and normal serum LysoGb3 levels.
Their clinical and biochemical ﬁndings are summarized in the Supple-
mentary Table A1 (Females 4 and 5). These females were diagnosed by
family screening.
3.3. Clinical and biochemical ﬁndings of 13 female patients with reduced α-
GalA activities and increased LysoGb3 levels
Thirteen of the 18 females, who hadα-GalA activity determinations,
had reduced α-GalA activities and increased serum LysoGb3 levels.
Their clinical and biochemical ﬁndings are summarized in Table A1 (Fe-
males 6–18). Two of these femaleswere diagnosedwith FD as index pa-
tients (Females 6 and 12), the other 11 by family screening. The
LysoGb3 levels were increased in all these patients with reduced α-
GalA activities.
4. Discussion
We identiﬁed three of 18 females with GLA-mutation conﬁrmed FD
in whom their α-GalA activities were normal, however, their serum
LysoGb3 levels weremarkedly increased (Table 1). In FD heterozygotes,
theα-GalA activities are often borderline normal or normal due to ran-
domX-chromosomal inactivation [3]. Ourﬁndings suggest that this bio-
marker may improve initial diagnose of clinically relevant FD,
particularly in female patients. These ﬁndings relate to which females
should be evaluated for treatment.
Importantly, the initiation of treatment is based on a conﬁrmed
pathogenic mutation, low levels of enzymatic activity and evidence of
early clinical manifestations. The LysoGb3 provides another indicator
of disease activity as it may reﬂect the overall total body substrate accu-
mulation. In heterozygotes with normal levels of α-GalA activity that
are asymptomatic, tissue biopsies have been used to determine which
women had marked glycosphingolipid accumulation. However, inva-
sive biopsies may not be feasible or acceptable in many heterozygotes
[17]. In heterozygotes from classic families, the serum LysoGb3 may
serve as a marker of tissue involvement to evaluate the need of treat-
ment. Although, normal LysoGb3 does not necessarily mean that there
is no need for treatment, as the clinical manifestations indicate thera-
peutic intervention.
Different methods have been used to measure LysoGb3 including
LC-MS/MS. Quality control materials and inter-laboratory testing are re-
quired to standardize LysoGb3 measurements among laboratories. This
will permit composition of results among laboratories in order to fur-
ther evaluate the potential use of this marker particularly in patients
Table 1
Current clinical and biochemical characteristics of the three females with theα-galactosi-
dase A activity within the normal range at the time of diagnosisa.
Female 1 Female 2 Female 3
α-gal A activity, % of lower
range
108 288 120
LysoGb3, ng/mL;
cut-off b 1.1 ng/mL
8.6 7.8 7.9
Current age, years 57 42 20
Age at diagnosis, years 55 39 12
Diagnosed as Index
patient
Family
screening
Family screening
Mutation c.796G N T c.1033 T N C c.744_745delTA
Predicted amino acid change p.Asp266Tyr p.Ser345Pro p.Phe248LeufsX7
Category Missense Missense Deletion
Phenotype Classic Classic Classic
Receiving ERT + + +
Hypohidrosis + − −
Acroparesthesia + − +
Angiokeratoma + − −
Cornea verticillata + + +
Cardiomyopathy − − −
eGFRb, mL/min/1.73m2 94 86 128
Urine prot/creatinine,
mg/mmol
Normal Normal 900
Stroke historyc 5 0 0
a Plus (+) or minus (−) indicates presence or absence of the clinical ﬁnding.
b According to CKD-EPI equation.
c Number of strokes.
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with the Later-Onset phenotype to improve its diagnostic utility, need
for treatment, and therapeutic monitoring.
Certainly, therapeutic decisions are not made by biomarker levels
only and extensive clinical characterization using a multidisciplinary
approach, a detailed family history and knowledge of previously report-
ed phenotypic descriptions of the speciﬁc GLAmutation are of utmost
importance to identify the phenotype and disease severity. Among our
females, two had both normal α-GalA activities and normal LysoGb3
levels, which emphasizes the need for further evaluation beyond the
use of biomarkers. As previously reported, many heterozygotes from
familieswith the Later-Onset phenotypewill have no FDmanifestations
and no serumLysoGb3 accumulation [12]. For example, the female, who
had a mutation resulting in the Later-Onset phenotype, had normal
LysoGb3 andwould have beenmisdiagnosed by the biomarker (Supple-
mental Table, Female 5). It should be noted that the severity of both
phenotypes can vary among affected males. Especially “Type 2” muta-
tions, where there is more variability in the onset and severity of the
cardiac and/or renal manifestations [18,19]. These are based on the
amount of residual α-GalA activity expressed by the given Later-Onset
mutation. In the Later-Onset heterozygotes, the LysoGb3 levels may be
very low or normal due to random X-chromosomal inactivation. Thus,
the LysoGb3 levels may not diagnose the mildly-affected or asymptom-
atic Later-Onset heterozygotes. Clearly, GLAmutation analysis remains
the diagnostic method of choice for Fabry heterozygotes, and the
LysoGb3 levels serve as biomarkers to evaluate the disease activity
and are helpful to determine when to intervene therapeutically.
Three recent reports have determined the plasma LysoGb3 levels in
males and females with the Classic, Later-Onset and benign GLAmuta-
tions: Lukas et al. [20], Niemann et al. [13] and Smid et al. [12]. Lukas
et al. from the Centogene laboratory, reported a variety of mutations
and their LysoGb3 levels (typically 1 or 2 females). Niemann et al. clas-
siﬁed patients clinically by new criteria and found that LysoGb3 levels
varied in 11womenwith pathogenic mutations. Smid et al. determined
the LysoGb3 levels in 14 non-classical patients and found an overlap
with normal levels regardless of α-GalA activities. Importantly, Smid
et al. recognized the need to further expand experience with LysoGb3
particularly in Later-Onset (or so called Non-classical) heterozygotes.
Therefore, we present our experience with 18 heterozygotes, with Clas-
sic, Later-Onset, and a benign mutation, in whom the enzymatic activi-
ties and LysoGb3 levels were determined. These studies further expand
experience with LysoGb3 and demonstrate that even classic female pa-
tients with normal enzyme levels have elevated LysoGb3 and further
conﬁrm that heterozygotes with Later-Onset mutations can have ele-
vated or normal LysoGb3 levels.
Higher LysoGB3 serum levels and lower leukocyte α-GalA activities
are not directly linked in heterozygotes presumably due to random X-
chromosomal inactivation. The leukocyte α-GalA activities reﬂect
“Lyonization” in bone marrow myeloid cells. Whereas the serum
LysoGb3 levels likely represent the level of Gb3 and LysoGb3 inmultiple
cell types in heterozygotes, the leukocyte α-GalA activity can be in the
normal range but reduced in other cell types such as myocytes and
podocytes so that the accumulation of Gb3 will be leaked into the plas-
ma and urine. Thus, the LysoGb3 levels can be a better indicator of over-
all disease severity. These studies are limited since the sample size is
relatively small and larger studies are needed to conﬁrm our ﬁndings.
In addition, the degree of random X-chromosomal inactivation is the
most prominent epigenetic factor that determines if a Type 1 Classic
or Type 2 Later-Onset heterozygote will be symptomatic [3]. It would
be useful to correlate the degree of “Lyonization” with the LysoGb3
levels. Such studies should be undertaken in the future.
5. Conclusion
LysoGb3 appears a useful biomarker in addition to the leukocyte en-
zyme activity in females. Themeasurement of LysoGb3 can improve the
initial diagnosis of FD, particularly in females with normal and/or
borderlineα-GalA activities, and the presentation of non-speciﬁc symp-
toms such as heat intolerance, pain, and gastrointestinal symptoms. As
illustrated by our study, LysoGb3 was a useful marker along with the
leukocyte α-GalA activity for the diagnosis of heterozygotes with FD,
and may be useful to assess which heterozygotes should be considered
for treatment, even though they have normal α-GalA activities.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2016.10.006.
Role of the funding source
The LysoGb3 measurements were provided by ARCHIMED Life Sci-
ence, Vienna, Austria. The laboratorymemberswere blinded to patients'
names and all clinical and biochemical information and had no role in
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mit the article for publication. The laboratory members (TPM and DCK)
participated in writing and approving the manuscript.
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